Company Overview of Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. operates as a biotechnology company. It offers OmniRat, an antibody platform that generates human monoclonal antibodies based on transgenic rats. Open Monoclonal Technology, Inc. has a strategic alliance with Crystal Bioscience, Inc. The company was founded in 2007 and is based in Palo Alto, California. As of January 8, 2016, Open Monoclonal Technology, Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
2747 Ross Road
Palo Alto, CA 94303
Founded in 2007
Key Executives for Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
December 17, 2015
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Open Monoclonal Technology, Inc., please visit www.openmonoclonaltechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.